RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:139552

Distal hereditary motor neuropathy, Jerash type

medium confidenceDisorder

Also known as: Autosomal recessive distal spinal muscular atrophy type 2 · dHMNJ

Query health: suspect — Only one of 3 strategies returned hits (phrase).

Publications

14

26.3th percentile

Trials

0

Interventional, condition-specific

Researchers

93

Distinct authors in sample

Gene link

SIGMAR1

Strong

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare, genetic, neuromuscular disease characterized by , symmetrical, moderate to severe, distal muscle weakness and atrophy, without sensory involvement, first affecting the lower limbs (towards the end of the first decade) and then involving (within two years) the upper extremities. Patients typically develop foot drop, pes varus, hammer toes and claw hands. Pyramidal tract signs (such as brisk knee reflexes and positive Babinski sign) with absent ankle reflexes are initially associated but regress as disease stabilizes (~10 years after onset).

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

DSMA2 · autosomal recessive distal spinal muscular atrophy type 2 · spinal muscular atrophy, distal, autosomal recessive, type 2

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Strong — SIGMAR1

  2. LiteraturePresent

    14 matched papers (9 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (SIGMAR1).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

14

14 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

14 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

9 in the last 10 years · medium confidence · 26.3th percentile (publications denominator)

Phrase hits: 14 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

93

Distinct author names in 14 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Falzone YM2 papers · 2023

    Neuromuscular Repair Unit, Institute of Experimental Neurology (InSpe), Division of Neuroscience, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.

    Papers in Europe PMC
  2. 02
    Kirby J2 papers · 2020

    Sheffield Institute for Translational Neuroscience (SITraN), Department of Neuroscience, University of Sheffield, Sheffield, UK, j.kirby@sheffield.ac.uk.

    Papers in Europe PMC
  3. 03
    Reilly MM2 papers · 2024

    Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases, UCL Queen Square institute of Neurology and National Hospital for Neurology and Neurosurgery.

    Papers in Europe PMC
  4. 04
    Rossor AM2 papers · 2024

    MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, London WC1N 3BG, United Kingdom.

    Papers in Europe PMC
  5. 05
    Aguzzi A1 paper · 2011
    Papers in Europe PMC
  6. 06
    Alghazwani Y1 paper · 2022

    Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.

    Papers in Europe PMC
  7. 07
    Alqahtani AM1 paper · 2022

    Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.

    Papers in Europe PMC
  8. 08
    Alqahtani T1 paper · 2022

    Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.

    Papers in Europe PMC
  9. 09
    Alshehri SA1 paper · 2022

    Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.

    Papers in Europe PMC
  10. 10
    Alsultan AA1 paper · 2016

    Sheffield Institute for Translational Neuroscience (SITraN), Department of Neuroscience, University of Sheffield, Sheffield, UK, j.kirby@sheffield.ac.uk.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

Broader category distal hereditary motor neuropathy also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Broader category: distal hereditary motor neuropathy

0

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Parent-category matching found a broader label but no interventional trials under it. How we count trials.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

Likely covered — the policy lists Spinal muscular atrophy as a category (Group 3), and this condition is a form of it. Confirm eligibility with a Centre of Excellence.

Group 3 — high-cost / lifelong therapy with careful selection

Up to ₹50 lakh per patient

Financial support at notified Centres of Excellence is the figure commonly cited in recent MoHFW/PIB statements. Many Group 3 patients also use the MoHFW voluntary-contribution / crowdfunding portal.

Eligibility and patient selection rules change. Verify with a CoE; the crowdfunding portal is a separate mechanism from CoE funding. Verify

Centres of Excellence (15)
  • All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
  • Maulana Azad Medical College — New Delhi, Delhi
  • Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
  • Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
  • Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
  • King Edward Memorial Hospital — Mumbai, Maharashtra
  • Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
  • Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
  • Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
  • All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
  • Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
  • All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
  • Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
  • All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
  • Assam Medical College & Hospital — Dibrugarh, Assam

Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Distal hereditary motor neuropathy, Jerash type" OR "Autosomal recessive distal spinal muscular atrophy type 2" OR "dHMNJ" OR "DSMA2" OR "spinal muscular atrophy, distal, autosomal recessive, type 2"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Spinal muscular atrophy, Jerash type

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Distal hereditary motor neuropathy, Jerash type" OR "Autosomal recessive distal spinal muscular atrophy type 2" OR "dHMNJ" OR "DSMA2" OR "spinal muscular atrophy, distal, autosomal recessive, type 2" OR "Spinal muscular atrophy, Jerash type" OR "SIGMAR1" OR "neuronopathy, distal hereditary motor, autosomal recessive" OR "hereditary motor neuron disease"

Recall-expansion terms: SIGMAR1, neuronopathy, distal hereditary motor, autosomal recessive, hereditary motor neuron disease

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"distal hereditary motor neuropathy"

Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • "DSMA2" also appears on ORPHA:139525

Ingested 2026-07-27T07:40:23.050Z